Author

nicole kulisek

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: RESULTS FROM THE PHASE 2 AND PHASE 3 CLINICAL PROGRAMMES
HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: RESULTS FROM THE PHASE 2 AND PHASE 3 CLINICAL PROGRAMMES

nicole kulisek  et al.

NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM
NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM

nicole kulisek  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

nicole kulisek  et al.

IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLI
IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLI

nicole kulisek  et al.

ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO
ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO

nicole kulisek  et al.

Item 1 - 5 / 5
1